Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07922759
PHASE4

Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery

Sponsor: University Medical Centre Ljubljana

View on ClinicalTrials.gov

Summary

This study aims to investigate whether different doses of locally infiltrated lidocaine affect inflammation, neurological biomarkers, and cognitive function in patients undergoing major head and neck cancer surgery. Major head and neck cancer surgery can cause substantial physical stress, inflammation, and changes in cognitive function after surgery. Lidocaine is a commonly used local anesthetic that may also have anti-inflammatory and protective effects on the nervous system. However, little is known about whether the dose of lidocaine injected into the surgical area influences these responses. This prospective, randomized pilot study will include 20 adult patients undergoing head and neck cancer resection followed by microvascular free-flap reconstruction at University Medical Centre Ljubljana, Slovenia. Participants will be randomly assigned to receive either 150 mg or 300 mg of lidocaine infiltrated into the surgical area at the beginning of surgery. Both groups will receive the same total volume of infiltration solution and the same dose of adrenaline. Blood samples will be collected before surgery, six hours after surgical incision, and on postoperative days 1, 2, and 6 to measure inflammatory and neurological biomarkers. Cognitive function will be assessed before surgery, on postoperative day 6, and three months after surgery. The study will explore whether the higher dose of lidocaine is associated with differences in inflammatory responses, neurological biomarkers, and postoperative cognitive function. The findings will help inform the design of larger future clinical studies.

Official title: Lidocaine and Neuroimmunomodulation: The Effect of Local Anesthetic Concentration in Head and Neck Cancer Resections

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2026-06-20

Completion Date

2028-12

Last Updated

2026-11-06

Healthy Volunteers

No

Interventions

DRUG

Lidocaine HCl 1%

Lidocaine hydrochloride 1% solution will be administered by local infiltration into the surgical field at the beginning of head and neck cancer surgery. Participants will be randomized to receive one of two doses: Higher-dose group: 30 mL of 1% lidocaine (300 mg), combined with 0.5 mg of adrenaline and 20 mL of 0.9% sodium chloride solution. Lower-dose group: 15 mL of 1% lidocaine (150 mg), combined with 0.5 mg of adrenaline and 35 mL of 0.9% sodium chloride solution. Both groups will receive a total infiltration volume of 50 mL and an identical adrenaline dose (0.5 mg). The intervention will be administered once, at the beginning of surgery.

Locations (1)

University Medical Centre Ljubljana

Ljubljana, Slovenia